{"name":"Dyno Therapeutics","slug":"dyno","ticker":"Private","exchange":"Private","domain":"dynotx.com","description":"Dyno Therapeutics is a private company focused on gene therapy and AI-driven drug design. The company is developing novel treatments for various diseases. With its cutting-edge technology, Dyno Therapeutics aims to revolutionize the field of gene therapy. The company has a strong pipeline of promising candidates.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Eric Kelsic","sector":"Gene Therapy / AI Drug Design","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1B+ (est. last valuation)","metrics":{"revenue":60000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-15","type":"deal","headline":"Dyno Therapeutics Raises $100M in Series C Funding","summary":"Dyno Therapeutics announced the completion of a $100 million Series C funding round, led by new investor, 5AM Ventures.","drugName":"","sentiment":"positive"},{"date":"2022-06-01","type":"trial","headline":"Dyno Therapeutics Initiates Phase 1 Clinical Trial for Gene Therapy Candidate","summary":"Dyno Therapeutics announced the initiation of a Phase 1 clinical trial for its gene therapy candidate, targeting a rare genetic disorder.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNUEtTenZlOHYzQnJTaTE3aHgyVzQzcmY0cVU5SnBPQnc5YzZYaXFOVTVlMjNCN1ZPeEN2dG92ZlM2d2d4dFphQ0xKNVRyOVNNTE5MS2ZHTy1xT3UwM09vUlNpQmRvT2ZXVEIzV0otNi10RVFqeTZsSXJSSHJwUTdyM3NNTWIwUDlsTXVfQlc0UQ?oc=5","date":"2026-01-06","type":"pipeline","source":"drugdiscoverytrends.com","summary":"50 cell and gene therapy leaders to watch in 2026 - drugdiscoverytrends.com","headline":"50 cell and gene therapy leaders to watch in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOZEtrWjZZU0x1ajdXa3JnWkk3VUt6b2w3cDVBLWRNejhNenFvX05ObndFMm4xRHBUdnlsTXE4N3lyUV9KaVhBR2ZoWDdMSXFtZnNLQlhOWVdtSEVhd2hwRjE3WWRZUTByQ2YwWU9IcHhrdzI3dTY0QTFScDJNNHNrWkNRVUpnZGdPczFnekZsUUY4MkFVLWhrWk5R?oc=5","date":"2025-11-12","type":"deal","source":"Pharmaceutical Technology","summary":"Dyno Therapeutics and Trisk Bio partner for strategic manufacture - Pharmaceutical Technology","headline":"Dyno Therapeutics and Trisk Bio partner for strategic manufacture","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOY1FSeXlFamZseUNEWVItQ3psajBCb3d0a0NyVFRXLXR1N0ctajlzYnhFTDVyV2N6RHR6Mkk3dXRfcnFpTTJMN1B4ejZOaVNXcHlrYXA0eFhSRDRreGJOeU96Vko0bERRMElpWm84bE9jZzI2V1JWZDZfS0pXNHJielBfVm11SndyUUx3Rk5FTkh5SnhDcC1KU1l5THlPek9NRGh4bG1JVmo?oc=5","date":"2025-03-10","type":"pipeline","source":"Fierce Pharma","summary":"UPDATE: Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment - Fierce Pharma","headline":"UPDATE: Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPaVVxUUJHMF9kaTRQWmNEbUxZWWZpY252b0dia3RtRU94OHdQZERrZWw3OVNhWUpKNmpmdlZSQS1jaTBJbU9LR29rN0doNVdZU3ZXNFpjenpwdUlveFdWZnQ0NUFkbW9WeldxWjhWZ05LT1B1Z1ZURzVETUJiY1RsYkxNclVweklnQVlpaFphcmo?oc=5","date":"2024-12-20","type":"pipeline","source":"drugdiscoverytrends.com","summary":"100 cell and gene therapy leaders to watch in 2025 - drugdiscoverytrends.com","headline":"100 cell and gene therapy leaders to watch in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPQ0pteTAxeUZPc1NBM1d3RC14X3JPcFU0SVhIcmo5bW44dW9XemxKdDhIZUd5RVVVSkR1QzdQT3lvNHB5ZWQ1eVF6SkNEYVBaTmdhR3U4MW1DR2l4Z0lmSnhwTDNVUnRCMnVPb0pTTWltUzM0Q0c0QWZHazJBMXB3MkJjMnhkcng2dnFlOHM4RmhocHZxQmZhdFZ2c1Zzc2ZPYjBReUhQM05uQ2tPckFnMGdkVQ?oc=5","date":"2024-10-30","type":"pipeline","source":"Pharmaceutical Technology","summary":"Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders - Pharmaceutical Technology","headline":"Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOeFFnM0ROMlpJLUJRM3RySWNvbDN2YlpVVGdZbmh5cjdmWkhRVzlmZUZFWURLbzlVUl9tQWdNMUdoOHNmVU11V21iRjFqSUE0XzliRVNTSmM5aFJHUEJGX05rSlFyTjNPR2Fvb3hkZjNVZHNnTVVJQW4yUFEzTFM5UUpzSU5POUFZQjVydUQwQQ?oc=5","date":"2024-10-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"Dyno and Roche collaborate for neurological gene therapies - Pharmaceutical Technology","headline":"Dyno and Roche collaborate for neurological gene therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQnJzck5HQnI4SWhDeUxsYkhSdkFSWG9oN3M2YVdvM0tMRlVRbnVNR0I3X1JJY1YxSDNkeXdSVTdITU85aVlHRVMtVDdvOXZtcHM5VzNIMGZuT3ZrRXlXMUhzdUF0Y2V0S3pCSGIxWV81UDhXMHlkQ3E0ZDlPUVBTRnlibVBBZTFuSGpV?oc=5","date":"2023-03-10","type":"pipeline","source":"drugdiscoverytrends.com","summary":"The top 100 cell and gene therapy companies to watch in 2023 - drugdiscoverytrends.com","headline":"The top 100 cell and gene therapy companies to watch in 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxONDJfU3pXaUVpamhZR2l2TklNMU56a1lhMnlMY0UzSzFIUktKR1dQa0Q4a0tLNW10R2h1QWZZYi0xNEM4S2NJaUp0dWFUWVlXdG9ONUVSWmhJOV9fRXRQX3NpNnA1TmJpSG5wclF5OTd4SS1JX19yWE1kS1MtTGM2R0NyUDBQSUUyVGZfY2hodFFsekQ1VlB5cS1UbXpmMXRUT1czVS1BVXQ5ZHFaWVVrUE0wYUJ4X0laTWkzLXJpdl9RYlJidzM0OHVnanFMYlZyN2FtNmdKdWFBVGxTQXFYcml0dGgxR25GX3BvQmVvcC0xOXlXa3V2TV9LTS01OGc3a2VwNDllb1AySHBCRUNhMXYxUEhTaDlxSmhWaW5heUthUTNBWGpvR0dn?oc=5","date":"2021-12-01","type":"deal","source":"PR Newswire","summary":"Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle - PR Newswire","headline":"Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNN0p2U2Y4LUdhbkNobWtZUmZaVG1iWDZSS3RMajdsWXNZT0IyUnhVVFdrNXhST2RNeHBqWURDT0xDQ0VvaVhLeUdKT3VlcEswcHNQSnVHS2pzVE1oU3JXUmd3TnkwTGtqcm1UaVY4YnFIdTFuWTZnN29ISHQzZUc5QjFhbHJlRnFiQVFtYg?oc=5","date":"2020-05-12","type":"deal","source":"Pharmaceutical Technology","summary":"Dyno Therapeutics launches with deals from Novartis and Sarepta - Pharmaceutical Technology","headline":"Dyno Therapeutics launches with deals from Novartis and Sarepta","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Intellia Therapeutics"],"therapeuticFocus":["Gene Therapy","Rare Genetic Disorders"],"financials":null,"yahoo":null}